GB0123756D0 - A novel chaperone-type of adjuvant for vaccination - Basic 1 - Google Patents

A novel chaperone-type of adjuvant for vaccination - Basic 1

Info

Publication number
GB0123756D0
GB0123756D0 GBGB0123756.9A GB0123756A GB0123756D0 GB 0123756 D0 GB0123756 D0 GB 0123756D0 GB 0123756 A GB0123756 A GB 0123756A GB 0123756 D0 GB0123756 D0 GB 0123756D0
Authority
GB
United Kingdom
Prior art keywords
vaccination
adjuvant
basic
type
chaperone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0123756.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Original Assignee
King's College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King's College London filed Critical King's College London
Priority to GBGB0123756.9A priority Critical patent/GB0123756D0/en
Publication of GB0123756D0 publication Critical patent/GB0123756D0/en
Priority to EP02765078A priority patent/EP1434794A2/en
Priority to AU2002329450A priority patent/AU2002329450A1/en
Priority to US10/491,679 priority patent/US20060264609A1/en
Priority to CA002463404A priority patent/CA2463404A1/en
Priority to JP2003532534A priority patent/JP2005512518A/ja
Priority to PCT/GB2002/004475 priority patent/WO2003029289A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0123756.9A 2001-10-03 2001-10-03 A novel chaperone-type of adjuvant for vaccination - Basic 1 Ceased GB0123756D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0123756.9A GB0123756D0 (en) 2001-10-03 2001-10-03 A novel chaperone-type of adjuvant for vaccination - Basic 1
EP02765078A EP1434794A2 (en) 2001-10-03 2002-10-03 Fragments of heat shock proteins and their use
AU2002329450A AU2002329450A1 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use
US10/491,679 US20060264609A1 (en) 2001-10-03 2002-10-03 Use of heat shock proteins
CA002463404A CA2463404A1 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use
JP2003532534A JP2005512518A (ja) 2001-10-03 2002-10-03 熱ショックタンパク質の使用
PCT/GB2002/004475 WO2003029289A2 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0123756.9A GB0123756D0 (en) 2001-10-03 2001-10-03 A novel chaperone-type of adjuvant for vaccination - Basic 1

Publications (1)

Publication Number Publication Date
GB0123756D0 true GB0123756D0 (en) 2001-11-21

Family

ID=9923176

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0123756.9A Ceased GB0123756D0 (en) 2001-10-03 2001-10-03 A novel chaperone-type of adjuvant for vaccination - Basic 1

Country Status (7)

Country Link
US (1) US20060264609A1 (enExample)
EP (1) EP1434794A2 (enExample)
JP (1) JP2005512518A (enExample)
AU (1) AU2002329450A1 (enExample)
CA (1) CA2463404A1 (enExample)
GB (1) GB0123756D0 (enExample)
WO (1) WO2003029289A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151049A (zh) * 2004-06-15 2008-03-26 纽约血液中心有限公司 旋盘尾丝虫的天然产物的佐剂和免疫加强性能
US20090118173A1 (en) * 2006-01-24 2009-05-07 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
CN101801402B (zh) * 2007-07-06 2013-08-28 乌得勒支大学控股有限公司 炎性疾病和自身免疫疾病的治疗和预防
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
US20170260286A1 (en) * 2016-03-10 2017-09-14 The General Hospital Corporation Antigen-Binding Fusion Proteins with Modified HSP70 Domains
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018049118A1 (en) * 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
AU2021357131A1 (en) * 2020-10-09 2023-05-25 Zeria Pharmaceutical Co., Ltd. Novel use of mycobacterium tuberculosis extract
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777890B1 (fr) * 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
GB9930443D0 (en) * 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
EP1209226A3 (en) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
WO2002061113A2 (en) * 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation

Also Published As

Publication number Publication date
JP2005512518A (ja) 2005-05-12
WO2003029289A3 (en) 2003-08-28
AU2002329450A1 (en) 2003-04-14
CA2463404A1 (en) 2003-04-10
EP1434794A2 (en) 2004-07-07
US20060264609A1 (en) 2006-11-23
WO2003029289A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
GB0105895D0 (en) Novel compounds
HUP0402027A3 (en) Process for the preparation of a xantophyll
HUP0304091A3 (en) Methods for the production of 3-0-deactivated-4'-monophosphoryl lipid a (3d-mla)
AU2002359165A8 (en) Novel compounds
IL160193A0 (en) Process for the preparation of a 14-hydroxynormorphinone derivative
GB0104259D0 (en) Novel compounds
GB0123755D0 (en) A novel chaperone-type of adjuvant for vaccination - advanced 2
GB0102713D0 (en) Novel compounds
GB0102470D0 (en) Novel compounds
GB0103866D0 (en) Novel compounds
GB0106570D0 (en) A set of parts
GB0102578D0 (en) Novel Compounds
GB0100186D0 (en) Novel compounds
GB0102577D0 (en) Novel Compounds
GB0106155D0 (en) Novel Compounds
GB0102570D0 (en) Novel Compounds
GB0100179D0 (en) Novel compounds
GB0100182D0 (en) Novel compounds
GB0105234D0 (en) Novel compounds
GB0102571D0 (en) Novel Compounds
GB0106156D0 (en) Novel compounds
GB0100037D0 (en) Novel compounds
GB0102575D0 (en) Novel Compounds
GB0100180D0 (en) Novel compounds
GB0100185D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)